Source-grounded facts extracted from Arcutis Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $105.4 million.
“--- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update • Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 • Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of”
David Topper departed as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.”
Latha Vairavan was appointed as Senior Vice President and Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.”
Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.6 million.
“3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 | arcutis.com First Quarter 2024 Summary Financial Results Product revenues for the quarter ended March 31, 2024 were $21.6 million compared to $2.8 million for the corresponding period in 2023. Revenues for the quarter were $15.0 million for ZORYVE (roflumilast) cream 0.3% and $6.5 million for ZORYVE”
John Smither resigned as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.”
John Smither changed role as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.”
David Topper was appointed as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“On April 10, 2024, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of David Topper as the Company’s Chief Financial Officer, effective as of April 10, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.